Publications in collaboration with researchers from Hospital Universitario Puerta de Hierro (25)

2024

  1. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  2. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

  3. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  4. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

2023

  1. A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study

    Hematology (United Kingdom), Vol. 28, Núm. 1

  2. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  3. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

    Frontiers in Oncology, Vol. 13

  4. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  5. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

    Blood, Vol. 142, Núm. 18, pp. 1518-1528

  6. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

    Haematologica, Vol. 108, Núm. 10, pp. 2753-2763

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

    Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239

  3. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

  4. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  2. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

    Leukemia, Vol. 35, Núm. 1, pp. 245-249

  3. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

  4. Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?

    Blood, Vol. 138, Núm. 19, pp. 1901-1905

2020

  1. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  2. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

    Blood Cancer Journal, Vol. 10, Núm. 10